Pages

Monday, August 5, 2019

Foamix Submits New Drug Application to US FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea - PRNewswire

Foamix Submits New Drug Application to US FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea  PRNewswire

REHOVOT, Israel and BRIDGEWATER, N.J., Aug. 5, 2019 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty ...


Foamix Submits New Drug Application to US FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea - PRNewswire
Read More
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)